巴西脑膜炎球菌病流行病学(2005-2018)及MenC疫苗接种影响
该研究基于巴西国家监测系统2005-2018年数据,分析MenC结合疫苗纳入常规免疫前后脑膜炎球菌病发病与死亡变化。共报告31,108例病例和6,496例死亡,<5岁儿童占35%。疫苗接种后<5岁儿童MenC疾病显著下降,但MenW和MenB仍值得关注,且疫苗覆盖率有所下降。
要点
- MenC疫苗接种后<1岁婴儿MenC发病率从3.30/10万降至1.08/10万。
- 1-4岁儿童MenC发病率从1.44/10万降至0.42/10万。
- 2018年婴儿疫苗覆盖率降至83%,青少年接种率低于20%。
核心结论
- MenC疫苗引入后巴西脑膜炎球菌病发病率和死亡率显著下降,尤其<5岁儿童,主要由MenC血清群减少驱动。
- MenW和MenB血清群疾病仍值得关注,且疫苗覆盖率下降和地区差异需持续监测。
研究设计与样本
- 基于国家监测系统的描述性时间序列分析,比较疫苗接种前(2005-2009)和接种后(2011-2018)的发病率和死亡率。
- 2005-2018年共报告31,108例脑膜炎球菌病病例和6,496例死亡。
- 血清群分析比较接种前(2007-2009)和接种后(2011-2018)时期。
主要发现
- 2005-2018年35%的病例和死亡发生在<5岁儿童。
- 2012年以来所有年龄组发病率和死亡率稳步下降,接种后<1岁、1-4岁、5-9岁和10-14岁儿童发病率和死亡率显著降低。
- <1岁婴儿MenC发病率从3.30/10万(2007-2009)降至1.08/10万(2011-2018)。
- 1-4岁儿童MenC发病率从1.44/10万降至0.42/10万。
- MenB疾病也观察到减少;2005-2018年报告748例MenW病例。
关键数值与推荐
- 初始婴儿疫苗覆盖率全国>95%,但2018年降至83%。
- 2017/18年青少年接种率<20%。
临床怎么用
- 维持高疫苗覆盖率以巩固MenC疾病下降成果。
- 关注MenW和MenB血清群疾病变化,适时评估疫苗策略。
- 针对地区差异加强免疫规划实施和监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningococcal disease (MD) presents a substantial public health problem in Brazil. Meningococcal C conjugate (MenC) vaccination was introduced into the routine infant immunization program in 2010, followed by adolescent vaccination in 2017. We evaluated changes in national and regional MD incidence and mortality between 2005 and 2018, serogroup distribution and vaccine coverage. METHODS: Data were obtained from national surveillance systems from 2005 to 2018. Age-stratified incidence and mortality rates were calculated and a descriptive time-series analysis was performed comparing rates in the pre-(2005-2009) and post-vaccination (2011-2018) periods; MD due to specific meningococcal serogroups were analyzed in the pre-(2007-2009) and post-vaccination (2011-2018) periods. RESULTS: From 2005 to 2018, 31,108 MD cases were reported with 6496 deaths; 35% of cases and deaths occurred in children < 5 years. Incidence and mortality rates declined steadily since 2012 in all age-strata, with significantly lower incidence and mortality in the post-vaccine introduction period in children aged < 1-year, 1-4 years, 5-9 years and 10-14 years. A significant decline in MenC disease in children < 5 years was observed following MenC vaccine introduction; infants < 1 year, from 3.30/100,000 (2007-2009) to 1.08/100,000 (2011-2018) and from 1.44/100,000 to 0.42/100,000 in 1-4-year-olds for these periods. Reductions in MenB disease was also observed. MenW remains an important cause of MD with 748 cases reported across 2005-2018. While initial infant vaccination coverage was high (>95% nationwide), this has since declined (to 83% in 2018); adolescent uptake was < 20% in 2017/18). Regional variations in outcomes and vaccine coverage were observed. CONCLUSION: A substantial decline in incidence and mortality rates due to MD was seen following MenC vaccine introduction in Brazil, especially among children < 5 years chiefly driven by reductions in MenC serogroup. While these benefits are considerable, the prevalence of MD due to other serogroups such as MenW and MenB remains a concern. A video summary linked to this article can be found on Figshare: https://doi.org/10.6084/m9.figshare.13379612.v1.
引用
- Aparecido Nunes A, De Jesus Lopes De Abreu A, Cintra O, et al. Meningococcal disease epidemiology in Brazil (2005-2018) and impact of MenC vaccination. Vaccine. 2020. PMID: 33358262. doi:10.1016/j.vaccine.2020.11.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。